Fenticonazole nitrateCAS# 73151-29-8 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 73151-29-8 | SDF | Download SDF |
| PubChem ID | 51754 | Appearance | Powder |
| Formula | C24H21Cl2N3O4S | M.Wt | 518.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (192.90 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 1-[2-(2,4-dichlorophenyl)-2-[(4-phenylsulfanylphenyl)methoxy]ethyl]imidazole;nitric acid | ||
| SMILES | C1=CC=C(C=C1)SC2=CC=C(C=C2)COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl.[N+](=O)(O)[O-] | ||
| Standard InChIKey | FJNRUWDGCVDXLU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C24H20Cl2N2OS.HNO3/c25-19-8-11-22(23(26)14-19)24(15-28-13-12-27-17-28)29-16-18-6-9-21(10-7-18)30-20-4-2-1-3-5-20;2-1(3)4/h1-14,17,24H,15-16H2;(H,2,3,4) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Fenticonazole nitrate Dilution Calculator
Fenticonazole nitrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.929 mL | 9.6451 mL | 19.2901 mL | 38.5802 mL | 48.2253 mL |
| 5 mM | 0.3858 mL | 1.929 mL | 3.858 mL | 7.716 mL | 9.6451 mL |
| 10 mM | 0.1929 mL | 0.9645 mL | 1.929 mL | 3.858 mL | 4.8225 mL |
| 50 mM | 0.0386 mL | 0.1929 mL | 0.3858 mL | 0.7716 mL | 0.9645 mL |
| 100 mM | 0.0193 mL | 0.0965 mL | 0.1929 mL | 0.3858 mL | 0.4823 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ferruginine
Catalog No.:BCN1911
CAS No.:73069-63-3
- Arecoline
Catalog No.:BCN8537
CAS No.:73069-28-9
- Scutebarbatine D
Catalog No.:BCN8536
CAS No.:910099-76-2
- Praeruptorin D
Catalog No.:BCN4990
CAS No.:73069-28-0
- (+)-Praeruptorin A
Catalog No.:BCN4989
CAS No.:73069-27-9
- Praeruptorin A
Catalog No.:BCN4987
CAS No.:73069-25-7
- Atractylenolide II
Catalog No.:BCN1044
CAS No.:73069-14-4
- Atractylenolide I
Catalog No.:BCN1043
CAS No.:73069-13-3
- Epigomisin O
Catalog No.:BCN2862
CAS No.:73036-31-4
- Atractylenolide III
Catalog No.:BCN1045
CAS No.:73030-71-4
- CyPPA
Catalog No.:BCC7526
CAS No.:73029-73-9
- 15-Isopimarene-8,18-diol
Catalog No.:BCN4287
CAS No.:73002-86-5
- Effusol
Catalog No.:BCN2928
CAS No.:73166-28-6
- (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin
Catalog No.:BCC6011
CAS No.:73168-24-8
- Baptifoline
Catalog No.:BCN7988
CAS No.:732-50-3
- Xamoterol hemifumarate
Catalog No.:BCC6861
CAS No.:73210-73-8
- Chloranthalactone E
Catalog No.:BCN7466
CAS No.:73215-92-6
- Remoxipride hydrochloride
Catalog No.:BCC6844
CAS No.:73220-03-8
- ITF2357 (Givinostat)
Catalog No.:BCC2150
CAS No.:732302-99-7
- Florfenicol
Catalog No.:BCC8984
CAS No.:73231-34-2
- Methylnaltrexone Bromide
Catalog No.:BCC1740
CAS No.:73232-52-7
- Moringin
Catalog No.:BCN7722
CAS No.:73255-40-0
- 5-O-Caffeoylshikimic acid
Catalog No.:BCN7929
CAS No.:73263-62-4
- 1,4-Dihydro-1,2-dimethyl-4-oxo-3-quinolinecarboxylic acid
Catalog No.:BCN1369
CAS No.:73281-83-1
Fenticonazole nitrate for treatment of vulvovaginitis: efficacy, safety, and tolerability of 1-gram ovules, administered as ultra-short 2-day regimen.[Pubmed:15216954]
J Chemother. 2004 Apr;16(2):179-86.
Because of its potential as a low cost first-line monotherapy for the most common vulvovaginal infections, we evaluated Fenticonazole nitrate in a prospective, open-label, multicenter pilot study with 101 sexually active women (per-protocol; 16 to 61 years of age) with vulvovaginitis involving single or mixed infections with Candida albicans, Trichomonas vaginalis, and/or Gardnerella vaginalis. Fenticonazole nitrate (1 g) was administered as vaginal ovules, once daily on days 1 and 3. Eradication (direct phase-contrast microscopy of vaginal swabs and/or microbiological culture) on day 8 was 90% (C. albicans, 26/29, p < 0.001), 70% (T. vaginalis, 7/10, p = 0.161), 67% (G. vaginalis, 22/33, p < 0.009), and 45% (mixed infection, 13/29, p = 0.001). After 28 days, relapse was 0% for candidiasis and trichomoniasis, 27% (6/22) for G. vaginalis, and 23% (3/13) for mixed infection. Overall, eradication of all offending pathogens was achieved in 67% of the total per-protocol population, with a relapse rate of only 16%. Score sums for symptoms improved from 7.0 (baseline) to 1.7 (day 8), and 0.71 (day 28), (p < 0.001). Treatment was safe and well tolerated. The results of our pilot study suggest that application of Fenticonazole nitrate 1 g intravaginal ovules on 2 alternate days is a suitable first-line treatment of vulvovaginitis with acceptable broad-spectrum efficacy against the most commonly involved pathogens and with a low rate of early relapse, reserving antibiotics for patients with treatment failure or relapse of infection. Our results should encourage further examination of this approach in larger and well controlled clinical trials.
[Efficacy and tolerance of 200 mg of fenticonazole versus 400 mg of miconazole in the intravaginal treatment of mycotic vulvovaginitis].[Pubmed:12017948]
Ginecol Obstet Mex. 2002 Feb;70:59-65.
OBJECTIVE: Fenticonazole is an imidazole derivative with a broad-spectrum antifungal activity mainly against Candida albicans. Fenticonazole nitrate was compared to myconazole vs. test efficacy, tolerance and treatment compliance in-patients with mycotic vulvovaginitis. PATIENTS AND METHOD: Eighty outpatients with mycotic vulvovaginitis were included and randomly placed in two groups of forty patients each one. Each group was either given 200 mg of Fenticonazole nitrate intravaginal ovules or 400 mg of myconazole vaginal ovules on a daily basis for three days. Before the pharmacological treatment, each patient was evaluated clinically and microbiologically, as well as at the end of treatment (day 7-10) and one-month (28 days) after treatment. All patients gave informed consent to participate in the trial. RESULTS: No statistical differences were found between either treatment group during the anthropometric and demographic evaluation, neither in the signs and clinical symptoms of infection. Both treatment groups were considered as comparable. At after treatment evaluation (7-10 days) it was observed disappearance of almost all symptoms. At the final evaluation this fact was even more evident (day 21-28). At the study's completion, clinical efficacy (symptoms relief) was considered satisfactory in 100% (40/40) of the cases in the fenticonazole group and 97.5% (39/40) of myconazole group (one way ANOVA [GLM] analysis). The microorganisms more frequently isolated as the causing agents of infection in both groups were Candida albicans, 93% in the fenticonazole group and 85% in the myconazole group. Upon the study's completion, the microbiological efficacy was considered as successful in 97.5% of the cases in both groups (chi square [x2] analysis). The patient's compliance to the treatment was considered satisfactory in 100% in the fenticonazole group and 97.5% in the myconazole group. Tolerance was considered excellent in 100% (40/40) of the fenticonazole cases and in 95% (38/40) of the myconazole cases. Nevertheless, 5% (2/40) of the patients in the myconazole group had minor adverse events that did not require treatment suspension. No adverse events were reported in the fenticonazole group. CONCLUSION: The results showed that both drugs are equally efficient in treating signs and symptoms of the infection as well as equally effective in the microbiological elimination of the causing agents of the mycotic vulvovaginitis.
[Evaluation of the time response of a single dose administration of fenticonazole nitrate].[Pubmed:8704823]
Contracept Fertil Sex. 1996 May;24(5):417-22.
174 women with vaginal candidosis confirmed by direct microscopic examination were treated with a single intravaginal Fenticonazole nitrate capsule. One third received a second intravaginal capsule three days later. Fenticonazole nitrate cream was also applied daily on the vulvar area in 94.2% of cases. Efficacy was excellent. After one week improvement and complete healing rates were 88% and 80%, respectively. On the second day of treatment pruritus and burning abated in 78% and 85% of women. Mycologic cure demonstrated by microscopic examination was obtained in 92% of cases. Treatment acceptance and tolerance were rated good or excellent by 98% and 92% of patients. Absence of abnormal vaginal discharge due to vaginal capsule was considered as an advantage by women. Results of this trial performed on a large number of patients confirm that product efficacy is fast.
